Neurocrine Biosciences heads into its May 1 Q1 results with short sellers meaningfully more aggressive than they were just a month ago — and options traders turning cautious on the day before the release.
The short interest buildup is the clearest signal. At 5.4% of the free float as of April 28, short interest is up 20% on the week and nearly 40% over the past month — a rapid accumulation that stands out even by biotech standards. Despite the climb, the borrow market remains relaxed: cost to borrow is just 0.32% APR, down sharply over the week, and availability is ample relative to the lending pool. That combination — rising short positions alongside easy and cheap borrowing — points to deliberate directional bets rather than any technical squeeze dynamic. The short score at 41.7 has ticked up over the past week, consistent with the buildup. Meanwhile, the stock itself has barely moved: NBIX closed at $131.23 on April 29, roughly flat on the week and up only 2% on the month. Options positioning turned notably more defensive on April 29 specifically, with the put/call ratio jumping to 1.49 from around 0.98 the prior session — though that reading remains below the 52-week high of 1.76 and only 0.77 standard deviations above the 20-day average of 1.28.
The bull-bear debate centres tightly on Crenessity. Bulls point to the drug's commercial infrastructure, Neurocrine's strong payer relationships, and expectations that the recent acquisition becomes accretive by FY26. EPS momentum ranks in the 92nd percentile on a 30-day basis and 79th on 90 days — forward estimates have been moving higher. Analysts have broadly ratcheted up price targets following the February earnings miss, with multiple firms raising targets in early April: Citigroup lifted to $242, Canaccord to $200, and Morgan Stanley to $185 while keeping an Equal-Weight rating — a split that captures the Street's uncertainty. The consensus mean target of $185.65 implies roughly 41% upside to the current price. Bears, however, focus on Crenessity's inconsistent sales trajectory, ongoing competitive pressure, and rising R&D costs that have already forced a trimmed financial outlook. The February print dropped the stock 10.6% in a single session, with an additional 6.7% lost over the following five days — the market has punished misses sharply here before.
Institutional ownership is stable and concentrated. BlackRock holds 12.8% and Vanguard 9.6%, both adding modestly in Q1. JP Morgan Asset Management added nearly 390,000 shares in the quarter, a more notable incremental commitment. Insider activity from February was largely routine — awards offset by concurrent sells following vest events — with no directional signal in either direction.
The earnings report will therefore test whether Crenessity's launch trajectory has inflected, and whether rising operational expenditure is tracking toward the accretion timeline the bulls are pricing in.
See the live data behind this article on ORTEX.
Open NBIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
